-
公开(公告)号：US12060421B2
公开(公告)日：2024-08-13
申请号：US17227642
申请日：2021-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mark F. Maurer , Tseng-hui Timothy Chen , Brigitte Devaux , Mohan Srinivasan , Susan H. Julien , Paul O. Sheppard , Daniel F. Ardourel , Indrani Chakraborty
CPC classification number: C07K16/2803 , A61P35/00 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y02A50/30
Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
-
22.发明授权公开(公告)号：US11802162B2
公开(公告)日：2023-10-31
申请号：US16663583
申请日：2019-10-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Changyu Wang , Nils Lonberg , Alan J. Korman , Mark J. Selby , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Guodong Chen , Richard Huang , Indrani Chakraborty , Haichun Huang , Susan Wong , Huiming Li
IPC: C07K16/28 , A61K47/68 , A61K39/395 , G01N33/68 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , C07K16/2818 , C07K16/2863 , G01N33/57492 , G01N33/6863 , G01N33/6872 , A61K47/6851 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N2333/70578 , G01N2333/7151
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20230051701A1
公开(公告)日：2023-02-16
申请号：US17737403
申请日：2022-05-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, JR. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC: C07K16/40 , C07K16/28 , C07K16/30 , A61K39/395 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US10690674B2
公开(公告)日：2020-06-23
申请号：US15578874
申请日：2016-06-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xi-Tao Wang , Olufemi A. Adelakun , Anne C. Lewin , Alan J. Korman , Mark J. Selby , Changyu Wang , Haichun Huang , Karla A. Henning , Nils Lonberg , Mohan Srinivasan , Michelle Minhua Han , Guodong Chen , Richard Y. Huang , Indrani Chakraborty , Susan Chien-Szu Wong , Huiming Li
IPC: G01N33/566 , G01N33/574 , C07K16/28
Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
公开(公告)号：US10683357B2
公开(公告)日：2020-06-16
申请号：US15474731
申请日：2017-03-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC: C07H21/04 , C12P21/06 , C12N15/87 , C12N1/20 , C12N5/20 , C12N15/00 , C07K16/28 , C07K16/30 , A61P35/00 , A61K39/395 , G01N33/574 , A61K39/00
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
Patent Agency Ranking
公开(公告)号：US09783606B2
公开(公告)日：2017-10-10
申请号：US14576278
申请日：2014-12-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
27.发明授权Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof 有权结合淋巴细胞活化基因-3（LAG-3）的抗体的优化及其应用公开(公告)号：US09505839B2
公开(公告)日：2016-11-29
申请号：US14093867
申请日：2013-12-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils Lonberg , Mohan Srinivasan
CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2818 , C07K16/2827 , C07K16/3061 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
Abstract translation: 本发明提供了与之前描述的抗LAG-3抗体（例如抗体25F7）（US 2011/0150892 A1）相比特异性结合LAG-3的分离的单克隆抗体，并具有优化的功能特性。 这些性质包括减少的脱酰胺位点，同时保持与人LAG-3的高亲和力结合，以及物理（即热和化学）稳定性。 还提供了编码本发明抗体的核酸分子，表达载体，宿主细胞和用于表达本发明的抗体的方法，以及免疫偶联物，双特异性分子和包含该抗体的药物组合物。 本发明还提供了用于检测LAG-3的方法，以及使用本发明的抗LAG-3抗体治疗刺激性免疫应答的方法。 还提供了其中抗体与至少一种另外的免疫刺激性抗体共同施用的联合治疗。
-
公开(公告)号：US20130315911A1
公开(公告)日：2013-11-28
申请号：US13898544
申请日：2013-05-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: C07K16/46
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
公开(公告)号：US20230295346A1
公开(公告)日：2023-09-21
申请号：US18180998
申请日：2023-03-09
Applicant: BRISTOL -MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, JR. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
IPC: C07K16/46 , A61K39/395 , A61K47/60 , A61K47/65 , C07K16/28
CPC classification number: C07K16/464 , A61K39/39533 , A61K47/60 , A61K47/65 , C07K16/2818 , C07K16/2878 , A61P29/00 , C07K2317/24 , C07K2317/515 , C07K2317/76 , C07K2319/50
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US11242393B2
公开(公告)日：2022-02-08
申请号：US16362411
申请日：2019-03-22
Applicant: Bristol-Myers Squibb Company
Inventor： Michelle Renee Kuhne , Alan J. Korman , Haichun Huang , Yiming Yin , Robert F. Graziano , Natalie A. Bezman , Pavel Strop , Richard Y. Huang , Guodong Chen , Mohan Srinivasan , Peter Sung Keun Lee , Gamze Ozlem Camdere
Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.037 seconds)
